To the casual observer, the optimistic discussion swirling around Humira biosimilars seems as if these competitor drugs will provide some relief to the country’s specialty drug problem. Unfortunately, the opposite is true; and our best opportunity in a generation to break the PBM stranglehold will be wasted.

VIVIO hosted an important webinar to answer critical questions facing employers and others responsible for managing specialty drugs. Topics included:

• How the PBM model led to the Humira monopoly and is standing in the way of change
• What you can do to effectively manage your Humira spend (spoiler alert, it has nothing to do with biosimilars)
• How dispensing with the obsolete PBM model can lower costs and prevent future monopolies